Valuation: Agenus Inc.

Market Cap 247M 217M 201M 185M 349M 23.88B 354M 2.4B 939M 11.69B 929M 909M 40.37B P/E 2026 *
8.32x
P/E 2027 * -34.6x
Enterprise Value 247M 217M 201M 185M 349M 23.88B 354M 2.4B 939M 11.69B 929M 909M 40.37B EV / Sales 2026 *
1.34x
EV / Sales 2027 * 1.88x
Free-Float
93.27%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Agenus Inc.

1 day+1.27%
1 week+10.38%
Current month+80.72%
1 month+81.91%
3 months+40.36%
6 months+63.61%
Current year+76.11%
1 week 4.78
Extreme 4.78
5.9
1 month 2.85
Extreme 2.85
8.7
Current year 2.71
Extreme 2.71
8.7
1 year 2.71
Extreme 2.71
8.7
3 years 1.38
Extreme 1.38
32.8
5 years 1.38
Extreme 1.38
135.8
10 years 1.38
Extreme 1.38
149.8
Manager TitleAgeSince
Chief Executive Officer 73 1994-03-30
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 2021-10-31
Director TitleAgeSince
Chairman 73 2010-11-03
Director/Board Member 68 2007-03-07
Director/Board Member 68 2006-12-06
Date Insider Type Main position Quantity % Market Cap.
7/10/26 Free

Chief Executive Officer

4,852 0.0117%
7/1/26 Free

Director

8,547 0.0205%
7/1/26 Free

Director

2,268 0.0054%
Change 5-day change 1-year change 3-year change Capi.($)
+1.27%+10.38%-9.64%-82.93% 247M
+1.53%-5.35%-4.59%+12.13% 46.06B
+1.12%-0.76%+378.26%+583.71% 38.91B
+0.72%+2.79%+8.23%+61.99% 35.57B
+6.91%-4.01%+5.95%-13.03% 33.13B
-0.87%-3.19%-1.27%+29.16% 26.42B
+0.24%-6.20% - - 16.61B
+22.29%-0.21%+10.55%+115.31% 15.08B
-4.56%-3.08%+6.31%+10.07% 14.08B
+6.80%-2.79%+3.58%-31.98% 12.81B
Average +3.54%-0.99%+44.15%+76.05% 23.89B
Weighted average by Cap. +2.95%-2.58%+68.62%+122.65%

Financials

2026 *2027 *
Net sales 185M 162M 150M 138M 260M 17.82B 264M 1.79B 701M 8.72B 693M 678M 30.13B 131M 115M 107M 98.25M 185M 12.68B 188M 1.27B 499M 6.21B 493M 483M 21.44B
Net income 44.8M 39.25M 36.44M 33.49M 63.1M 4.32B 64.03M 434M 170M 2.12B 168M 165M 7.31B -17.8M -15.6M -14.48M -13.3M -25.07M -1.72B -25.44M -172M -67.51M -840M -66.82M -65.38M -2.9B
Net Debt - -
Logo Agenus Inc.
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer with a comprehensive pipeline of immunological agents. The company is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The Company has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.
Employees
81
Date Price Change Volume
26-07-22 US$5.530 -0.90% 1,698,697
26-07-21 US$5.580 +12.27% 2,602,570
26-07-20 US$4.970 -0.80% 1,969,278
26-07-17 US$5.010 +0.20% 1,754,750
26-07-16 US$5.000 -0.20% 2,696,460
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
5.530USD
Average target price
30.00USD
Spread / Average Target
+442.50%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AGEN Stock